Cannabis addiction is one of the most undertreated substance use disorders in India - primarily because the belief that cannabis is 'not addictive' is so widely held that people rarely seek help until the consequences are severe. This belief is clinically incorrect. Cannabis use disorder is a recognised medical diagnosis. Approximately 1 in 10 regular cannabis users develop dependence, and among daily users that figure rises to 1 in 3. Cannabis is the second most commonly used drug in India after alcohol, and it is among the leading causes of substance use-related psychiatric presentations at Indian treatment centres.
At Athena Behavioral Health, cannabis addiction treatment is psychiatry-led and evidence-based across our NABH-accredited centres in Gurgaon, Delhi, and Noida. Treatment addresses the full clinical picture - the pattern of cannabis use, the mental health consequences, any co-occurring conditions, and the specific social and psychological factors that have sustained use.
What Is Cannabis Addiction?
Cannabis addiction - clinically termed Cannabis Use Disorder (CUD) - is defined as a pattern of cannabis use that causes significant impairment or distress, involving loss of control over use, continued use despite harm, and the development of tolerance and withdrawal. It is listed in the DSM-5 and is recognised by the WHO, NDDTC AIIMS, and all major international psychiatric bodies as a genuine clinical condition.
Cannabis is known in India by many names - charas, ganja, bhang, weed, hash, or simply 'stuff.' It is primarily smoked or consumed as edibles. While bhang has a traditional and legal cultural status in India (consumed at Holi and in certain religious contexts), all other cannabis products are classified as psychotropic substances under Schedule I of the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985, making their possession, sale, and use illegal.
Addressing the 'Cannabis Is Not Addictive' Belief
The single biggest barrier to people seeking cannabis addiction treatment in India is the widespread belief that cannabis cannot cause addiction. This belief is understandable - cannabis does not produce the physical collapse of heroin withdrawal, the visible intoxication of alcohol, or the cardiovascular urgency of cocaine. Its effects are subtler and its harms accumulate more slowly. But the clinical evidence is clear:
Cannabis use disorder occurs in approximately 9-10% of all people who use cannabis regularly - around 1 in 10
Among daily users, the rate rises to approximately 30-33% - 1 in 3
The 2019 National Survey on Extent and Pattern of Substance Use in India (NDDTC, AIIMS) found cannabis to be the second most used drug nationally after alcohol, with significant concentrations in Delhi, Haryana, UP, and Punjab
Cannabis is among the most common reasons for substance use-related treatment-seeking at Indian de-addiction centres
Cannabis withdrawal syndrome - involving irritability, anxiety, insomnia, reduced appetite, and cravings - is recognised in DSM-5 and can begin within 24 hours of stopping after regular use
High-potency cannabis (increasingly available in India through dark web and urban networks) carries a significantly higher risk of both dependence and psychosis than lower-potency traditional forms
The persistence of the 'not addictive' belief is one reason cannabis addiction in India is significantly undertreated. People often present to Athena after years of daily use - having dismissed concerns from family, attributed their declining motivation and mood to other causes, and tried and failed to stop multiple times on their own.
How Cannabis Affects the Brain
THC (tetrahydrocannabinol) - the primary psychoactive compound in cannabis - binds to CB1 receptors in the brain's endocannabinoid system. With regular use, the brain responds by reducing the number and sensitivity of these receptors - a process called downregulation. The result is that the person needs increasingly more cannabis to achieve the same effect (tolerance), and without cannabis, the now-undersupplied endocannabinoid system produces a withdrawal state. Research shows that CB1 receptor downregulation is measurable in regular users and is reversible - but takes approximately 4 weeks of abstinence to restore.
Beyond dependence, regular cannabis use affects the brain's dopamine system, prefrontal cortex function (executive decision-making, planning, and impulse control), and hippocampal memory circuits. These effects contribute to the constellation of symptoms most commonly seen in regular cannabis users presenting for treatment.
Signs and Symptoms of Cannabis Addiction
Heroin addiction affects the body, mind, and behaviour. Common signs include:
Behavioural signs
Using cannabis daily or near-daily, often first thing in the morning
Inability to enjoy activities, socialise, or relax without cannabis
Failed attempts to cut down or stop - trying to take 'breaks' and returning within days
Spending significant time obtaining, using, or recovering from cannabis
Continuing to use despite relationship problems, academic or work decline, or legal risk
Using cannabis alone and in secret rather than only in social contexts
Prioritising cannabis use over responsibilities, commitments, or personal health
Psychological and cognitive signs
Persistent low mood, anxiety, or irritability between uses - partially relieved by cannabis
Memory problems - particularly difficulty forming new memories or recalling recent events
Difficulty concentrating or sustaining attention without cannabis
Reduced motivation - the person seems less driven, less engaged, less interested than before
Emotional blunting - reduced capacity to feel strong positive or negative emotions without cannabis
Paranoia, anxiety, or panic during or after heavy use
In some cases: perceptual disturbances or psychotic symptoms
Physical signs
Red or bloodshot eyes, particularly in the evenings
Persistent cough or respiratory symptoms from smoking
Changes in appetite - increased appetite during use, reduced appetite when not using
Disrupted sleep - either sleeping excessively or, when stopping, severe insomnia
Smell of cannabis on clothing, breath, or belongings
Amotivational Syndrome - The Sign Most Families Describe
One of the most consistently reported consequences of long-term heavy cannabis use is what clinicians call amotivational syndrome - a pattern of reduced motivation, decreased activity levels, apathy, and declining functioning that develops gradually and can be difficult to attribute to cannabis use specifically.
Families often describe a person who was previously engaged, ambitious, and active - now spending most of their time at home, disengaged from work or studies, seemingly content to do very little, and resistant to any pressure to change. The person themselves often describes feeling that 'nothing seems worth the effort' and that cannabis is the only thing that makes them feel anything.
Amotivational syndrome in cannabis users is clinically significant because it resembles depression and is often misdiagnosed as such. It is important to note that it does not always resolve immediately on stopping cannabis - in some heavy users, motivation and engagement take weeks to months to restore as the endocannabinoid system recovers. This is a clinically important expectation to set at the start of treatment.
Cannabis and Mental Health - The Risks You Should Know
Cannabis and psychosis
The relationship between cannabis and psychosis is one of the most important - and most misunderstood - mental health risks of cannabis use. The evidence is now substantial: regular cannabis use, particularly of high-potency products, is associated with a significantly elevated risk of psychotic episodes. Daily cannabis users are approximately three times more likely to experience a first episode of psychosis compared with non-users. High-potency cannabis users face nearly double the risk compared with users of lower-potency products.
A Finnish study of 18,000 individuals with cannabis-induced psychosis found that nearly 50% were subsequently diagnosed with schizophrenia. Regular cannabis use increases the risk of developing schizophrenia by approximately four times - a risk comparable to the relationship between high cholesterol and heart disease. THC disrupts dopaminergic signalling in the prefrontal cortex and limbic system, producing psychotomimetic effects that in genetically vulnerable individuals can trigger a persistent psychotic disorder.
Cannabis is not safe for anyone with a personal or family history of psychosis, schizophrenia, or bipolar disorder. For people with these conditions, cannabis is one of the most significant modifiable risk factors for relapse and deterioration.
Cannabis and anxiety
Cannabis is widely used to manage anxiety - and in the short term, it can produce subjective relief. Over time, this relationship reverses. Regular cannabis use disrupts the brain's natural anxiety-regulation systems, producing increasing baseline anxiety that the person attempts to manage with more cannabis. Panic attacks are strongly associated with high-THC cannabis, particularly in people with anxiety predispositions. Many people presenting to Athena for cannabis treatment report that anxiety was their original reason for starting cannabis, and that anxiety is now significantly worse after years of use.
Cannabis and depression
The relationship between cannabis and depression is bidirectional. Depression increases the likelihood of cannabis use as self-medication. Regular cannabis use depletes the dopamine system over time, producing anhedonia - the inability to experience pleasure from ordinary life - that looks and feels like depression. Distinguishing cannabis-induced low mood from underlying depressive disorder requires a period of abstinence and psychiatric assessment, because the two are clinically indistinguishable during active use.
Cannabis and memory
THC directly impairs short-term memory formation during intoxication. With chronic use, these effects persist into periods of sobriety - regular cannabis users show measurable impairments in memory encoding, retrieval, and working memory compared to non-users. For students and young professionals - a significant proportion of Athena's cannabis treatment population - these cognitive effects are often the first functional consequence to be noticed by the person themselves or their family.
When Should You Seek Help?
Seek professional assessment if any of the following apply:
- Cannabis is used daily or near-daily and the person feels unable to stop despite wanting to
- Multiple attempts to stop or take breaks have failed
- Mood, motivation, memory, or academic/work performance have noticeably declined since cannabis use became regular
- The person experiences anxiety, irritability, or restlessness when they have not used cannabis for a day or two
- Family members have expressed concern about personality changes, withdrawal from social life, or declining functioning
- Cannabis use has begun to co-occur with other substance use - particularly alcohol or tobacco
- The person has experienced paranoia, panic attacks, or any psychotic symptoms during or after cannabis use
- Cannabis use began in adolescence - early-onset use carries significantly higher risk of dependence and cognitive impact
Cannabis Addiction Treatment at Athena Behavioral Health
Cannabis use disorder treatment is primarily psychological - there are no FDA or CDSCO-approved medications specifically for cannabis addiction, making structured behavioural therapy and psychiatry-led clinical management the core of evidence-based treatment. The combination of Motivational Enhancement Therapy and Cognitive Behavioural Therapy (MET + CBT) has the most consistent clinical evidence for cannabis use disorder - demonstrated across a Cochrane Review of multiple trials involving nearly 1,000 participants. At Athena, all treatment is psychiatry-led and personalised to the individual.
Comprehensive Psychiatric Assessment
All treatment at Athena begins with a thorough psychiatric assessment by a qualified psychiatrist. For cannabis addiction specifically, the assessment establishes: the duration, frequency, and quantity of cannabis use; the type of cannabis used and the route of administration; any history of psychotic symptoms, panic, or significant anxiety during or after use; the full mental health history including depression, anxiety, ADHD, and bipolar disorder; cognitive symptoms - particularly memory and concentration; family psychiatric history; and the functional impact on work, studies, relationships, and daily life. The assessment determines the appropriate treatment plan and, critically, whether co-occurring mental health conditions require concurrent psychiatric treatment.
Motivational Enhancement Therapy (MET)
MET is the single most evidence-supported intervention for cannabis use disorder at initial engagement. This is partly because cannabis addiction presents a specific motivational challenge: the person frequently does not accept that they have a clinical problem. They may acknowledge using cannabis heavily but genuinely believe it is harmless, that they could stop if they chose to, or that the benefits outweigh the costs. MET does not challenge this belief confrontationally - it explores it. Through structured reflection on the person's own values, goals, and the role cannabis plays relative to both, MET builds internal motivation for change that is far more durable than external pressure from family or professional ultimatums.
Cognitive Behavioural Therapy (CBT)
CBT for cannabis addiction addresses the specific cognitive and behavioural patterns that sustain use: the automatic assumption that cannabis is needed to sleep, to relax, or to manage social situations; the avoidance of emotional discomfort that cannabis enables; the rationalisation patterns ('I'll stop after this project / after Diwali / once I'm less stressed'); and the environmental and social cues - specific people, places, times of day, or emotional states - that trigger craving. CBT also builds practical skills for managing these triggers differently: alternative coping strategies for stress, anxiety, and boredom; sleep without cannabis; and social engagement without a substance that has previously mediated it.
The most effective approach, supported by the strongest evidence, is MET + CBT delivered over a minimum of 4 sessions across more than one month. The clinical evidence is clear that higher-intensity treatment produces better outcomes than brief interventions for cannabis use disorder.
Contingency Management
Where clinically appropriate, contingency management - a structured system of positive reinforcement for abstinence and treatment engagement - is integrated into the treatment plan. This approach has particular value in the early weeks of cannabis cessation, when the cognitive and motivational effects of the drug are still resolving and the pull of return to use is strongest.
Dual Diagnosis Assessment and Treatment
Cannabis use disorder co-occurs with other mental health conditions at a very high rate. Anxiety disorders, depression, ADHD, PTSD, and bipolar disorder are all significantly more common in people with cannabis use disorder than in the general population. In many cases these conditions preceded cannabis use and contributed to it - the person was self-medicating. In others, chronic cannabis use has created or worsened the condition. Either way, treating cannabis addiction without addressing the co-occurring condition dramatically increases relapse risk. At Athena, psychiatric assessment and treatment of co-occurring conditions runs concurrently with addiction treatment from the first day.
Cannabis-Induced Psychosis - Specialist Assessment
Where cannabis use has produced psychotic symptoms - paranoia, hallucinations, delusional thinking, or disorganised behaviour - specialist psychiatric assessment and management is required before standard addiction counselling can proceed. Cannabis-induced psychosis requires antipsychotic medication, psychiatric monitoring, and complete cannabis cessation as a clinical priority. Athena's psychiatry-led team manages this presentation specifically, distinguishing cannabis-induced psychotic disorder from primary psychotic illness - a distinction that requires clinical expertise and has significant treatment implications.
Withdrawal Management
Cannabis withdrawal is not medically dangerous in the way that alcohol or benzodiazepine withdrawal can be, but it is clinically significant and is a major driver of early relapse. Symptoms typically begin within 24 hours of stopping after regular use and include irritability and anger, anxiety and restlessness, insomnia, vivid or disturbing dreams, reduced appetite, nausea, and intense cravings. Acute symptoms peak at 2-4 days and largely resolve within 1-2 weeks, though sleep disturbance and cravings can persist for up to 45 days in heavy users. The clinical team at Athena manages withdrawal symptoms with appropriate support - sleep aids where necessary, anxiety management, and the close therapeutic support that prevents early relapse during this vulnerable period.
Individual Counselling
Individual counselling provides a space for the person to explore honestly why cannabis has played such a central role in their life - what needs it has been meeting, what it has given them, and what it has cost. For many regular cannabis users, the drug has become deeply embedded in identity, social life, stress management, creativity, and emotional regulation. Counselling works to understand this without judgement, and to build sustainable alternatives to each of these functions that do not depend on cannabis.
Family Counselling
Cannabis addiction is frequently invisible to families until it has been present for years - because the person appears functional, the impairments accumulate gradually, and the behaviour is not as dramatically disruptive as alcohol or heroin. When families do notice, they often struggle to communicate their concern in a way that the person accepts. Family counselling at Athena helps families understand what cannabis use disorder is, why the person genuinely believes they could stop if they chose to, how to express concern effectively without triggering defensiveness, and how to maintain the relationship while holding a clear position about the impact they are observing.
Relapse Prevention
Relapse prevention for cannabis addiction must specifically address the social and environmental ubiquity of cannabis - particularly for young adults in Delhi NCR's urban social environments where cannabis use is normalised and widely available. The relapse prevention plan maps high-risk situations (parties, friend groups where cannabis is present, specific emotional states, times of day, locations associated with past use) and develops concrete strategies for each. It also addresses the most common rationalisation pattern in cannabis relapse: 'I'll just have a small amount, I won't go back to daily use.' The clinical team works to address this belief directly, since for most people with cannabis use disorder, occasional or controlled use is not a sustainable outcome.
Cannabis Addiction in Specific Populations
Adolescents and young adults
Cannabis use that begins in adolescence carries significantly higher risks than adult-onset use. The developing brain - particularly the prefrontal cortex, which continues developing until approximately age 25 - is more vulnerable to the cognitive effects of THC. Adolescent-onset cannabis use is associated with greater impairment of memory, executive function, and IQ compared with adult-onset use, greater likelihood of developing cannabis use disorder, and earlier age of onset of psychotic disorders in vulnerable individuals. Athena's treatment team has specific experience in working with young people, and family involvement is a core component of treatment in this age group.
Professionals and executives
Cannabis use among professionals in Delhi NCR's corporate environment is more prevalent than is commonly acknowledged. The drug is used to decompress after high-pressure work days, to manage performance anxiety, to facilitate creative work, and to sleep. The functional impairments - memory, concentration, motivation - are often attributed to overwork rather than cannabis, delaying recognition and help-seeking. Athena's treatment team understands this professional context and can structure treatment that addresses confidentiality requirements and professional schedule constraints.
Cannabis and gaming
A specific co-occurring pattern increasingly seen at Athena Gurgaon is the combination of gaming addiction and cannabis use - with cannabis used to enhance the gaming experience, reduce inhibition in online social gaming, manage the frustration of competitive gaming, and transition between gaming and sleep. Where both patterns are present, treatment must address both - as each sustains the other.
What to Expect After Stopping Cannabis
Recovery from cannabis addiction is not simply about stopping use. The brain's endocannabinoid system - suppressed and dysregulated by chronic cannabis exposure - takes time to restore. The first weeks after stopping are often the hardest: sleep is disrupted, irritability is high, the ability to experience pleasure from ordinary activities is reduced, and cravings are intense. This phase is not permanent.
Research shows that CB1 receptor density - measurably reduced in regular cannabis users - begins to restore within 4 weeks of abstinence. Most people find that after 4-8 weeks without cannabis, sleep improves significantly, mood stabilises, and the ability to find enjoyment in activities that had previously seemed dull begins to return. Memory and concentration typically improve over 1-3 months. Motivation - particularly in people with established amotivational syndrome - may take longer, and this should be anticipated in the recovery plan rather than misinterpreted as ongoing depression.
Full recovery from cannabis addiction means building a life where cannabis is no longer needed - for relaxation, sleep, creativity, social ease, or emotional regulation. This requires not just abstinence but the development of sustainable alternative strategies for each of these functions, which is the core work of the therapy component of treatment.
Doctors Treating Cannabis Addiction at Athena
Cannabis Addiction Treatment Centres
Athena Behavioral Health provides cannabis addiction treatment across its NABH-accredited centres in Gurgaon, Delhi, Noida, and Guwahati. All centres offer psychiatry-led assessment, personalised treatment, and both residential and outpatient options.
Frequently Asked Questions
Is cannabis actually addictive?
Yes. Cannabis use disorder is a clinically recognised diagnosis in the DSM-5. Approximately 1 in 10 regular cannabis users develop dependence, rising to 1 in 3 among daily users. Cannabis produces both psychological dependence - where the person feels unable to function without it - and a recognised withdrawal syndrome when stopped. The widespread belief that cannabis is not addictive is one of the most significant barriers to people seeking treatment, and it is clinically incorrect.
What are cannabis withdrawal symptoms?
Cannabis withdrawal symptoms typically begin within 24 hours of stopping after regular use and can include irritability and anger, anxiety and restlessness, insomnia and disturbed dreams, reduced appetite, nausea, headaches, and intense cravings. Acute symptoms peak at 2-4 days and largely resolve within 1-2 weeks, though sleep disturbance and cravings can persist for up to 45 days in heavy long-term users. While cannabis withdrawal is not medically dangerous in the way alcohol withdrawal can be, it is uncomfortable and is the primary driver of early relapse.
Can cannabis cause psychosis?
The evidence for a link between cannabis use and psychosis is substantial. Daily cannabis users are approximately three times more likely to experience a first episode of psychosis compared with non-users. High-potency cannabis users face nearly double the risk of psychosis compared with low-potency users. A large Finnish study found that nearly 50% of individuals with cannabis-induced psychosis were later diagnosed with schizophrenia. Cannabis is contraindicated for anyone with a personal or family history of psychosis, schizophrenia, or bipolar disorder.
Why can't I stop using cannabis even though I want to?
Cannabis use disorder involves genuine changes to the brain's reward and motivation systems that make stopping difficult - not a lack of willpower. The endocannabinoid system, dysregulated by chronic cannabis use, produces cravings and emotional discomfort when cannabis is removed. These are neurobiological phenomena, not character weaknesses. This is why most people with cannabis use disorder cannot simply decide to stop - they need structured clinical support to address both the physical and psychological dimensions of dependence.
How long does cannabis addiction treatment take?
This varies significantly depending on the duration and severity of use, co-occurring conditions, and the treatment approach. A standard outpatient programme with MET + CBT typically runs 8-12 sessions over 2-3 months. More complex presentations - particularly those with co-occurring mental health conditions, cannabis-induced psychosis, or very long-standing daily use - typically require a longer engagement, sometimes including residential care for the initial stabilisation phase. The treating psychiatrist determines the appropriate programme length based on the individual's clinical profile.
Is cannabis legal in India?
Cannabis is classified as a psychotropic substance under Schedule I of the NDPS Act, 1985. Possession, sale, and use of cannabis (except bhang in certain states, which has a specific legal status) is illegal in India. The legal risk is an additional factor in why people with cannabis addiction are reluctant to seek treatment - they fear disclosing illegal activity to healthcare providers. At Athena, all treatment is completely confidential. Drug use history is protected medical information and is never shared without explicit consent.
Is treatment available for teenagers who use cannabis?
Yes. Athena treats adolescents and young adults with cannabis use disorder. Adolescent-onset cannabis use carries particularly significant risks to the developing brain, and early intervention is important. Treatment for young people involves the family as a core component, using family-based therapeutic approaches alongside individual work with the young person. The clinical approach is specifically adapted for the adolescent and young adult age group.
Is treatment confidential?
Completely. All assessments and treatment at Athena Behavioral Health are fully confidential. Given that cannabis use is illegal under the NDPS Act, many people are concerned about disclosure. No information about substance use history is shared with any third party - including employers, educational institutions, or law enforcement - without explicit written consent. Discretion is a clinical priority at Athena.
